Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181529 · ClinicalTrials.gov registry record · Phase 2
Effects of Psilocybin in Major Depressive Disorder
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03181529: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03181529 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181529, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. The primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2020-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181529
The ClinicalTrials.gov registry entry for NCT03181529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT03181529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181529 about?
NCT03181529 is a clinical study titled "Effects of Psilocybin in Major Depressive Disorder". The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. T...
What is the current status of trial NCT03181529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2017-08-10. Estimated completion is 2020-12-02.
What interventions are being tested in trial NCT03181529?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT03181529?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.